According to a preclinical study [21] on colorectal cancer cells, inhibition of EGFR decreases the expression of tissue factor; this would offer a stimulating hypothesis to explain our results; studies investigating specifically which tissue factors are affected in vivo by different treatments might result in the discovery and validation of biomarkers for treatment response and prediction of comorbidities like DVT/VTE. This evidence concerns the gene EGFR and deep vein thrombosis.